Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy

Transplantation

Volumn 92, Issue 1, 2011, Pages 48-53

  Lai, Chih Hung ^a   Cao, Kai ^a   Ong, Geraldine ^a   Naim, Mehrnoush ^a   Wang, Qi ^a   Mirocha, James ^b   Vo, Ashley ^a   Jordan, Stanley C ^a   Reinsmoen, Nancy L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Biostatistics Core   (United States)

Author keywords

High dose IVIG; HLA specific antibodies; Positive crossmatch; Pronase treatment; Rituximab

Indexed keywords

HLA A ANTIGEN; HLA ANTIBODY; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; PANEL REACTIVE ANTIBODY; RITUXIMAB;

ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE; CADAVER KIDNEY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HLA MATCHING; HUMAN; IMMUNOMODULATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DONOR SELECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOASSAY; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; ISOANTIBODIES; KIDNEY TRANSPLANTATION; TISSUE DONORS;

EID: 79959674425     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821eab8a     Document Type: Article

References (26)

1. The Organ Procurement and Transplantation Network 2007. Available at: http://optn.transplant.hrsa.gov/.
2. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: Whose problem is it? Front Biosci 2008; 13: 1396.
3. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
4. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003; 25: 119.
5. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
6. Vo A, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
7. Vo A, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
8. Jordan SC, Vo AA, Peng A, et al. Intravenous gammablobulin (IVIG):A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
9. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631.
10. Jordan SC, Tyan DB, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IGO2 trial. J AmSoc Nephrol 2004; 15: 3256.
11. Jordan SC, Vo A, Peng A, et al. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
12. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch:Asingle center's perspective. Pediatr Transplant 2004; 8: 535.
13. Zachary AA, Montgomery RA, Leffell MS. Desensitization protocols improving access and outcome in transplantation. Clin Appl Immunol 2005; 5: 373.
14. Crew RJ, Ratner LE. Overcoming immunologic incompatibility: Transplanting the difficult to transplant patient. Semin Dial 2005; 18: 474.
15. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.HumImmunol 2005; 66: 364.
16. Zachary AA, Montgomery RA, Jordan SC, et al. 14th internationalHLA and immunogenetics workshop: Report on understanding antibodies in transplantation. Tissue Antigens 2007; 69: 160.
17. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820.
18. Bray RA, Nickerson PW, Kerman RH, et al. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004; 29: 41.
19. Bearden CM, Agarwal A, Book BK, et al. Pronase treatment facilitates alloantibody flow cymetric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol 2004; 65: 803.
20. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457.
21. Sidner RA, Book BK, Agarwal A, et al. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13: 55.
22. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non- Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88(suppl 1): 637.
23. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949.
24. Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell population in vivo. Am J Transplant 2007; 7: 402.
25. Dorshkind K, Rawlings DJ. B-cell development: The hematopoietic hierarchy and B-lineage commitment. In: Hoffman, ed. Hematology: Basic principles and practice, [ed. 4]. Churchill Livingstone Elsevier, Philadelphia 2005.
26. Lai CH, Okhovat J, Ong G, et al. Better dynamic antibody detection range using flow single antigen assay than Luminex single antigen assay. Hum Immunol 2010; 71: S62.